Events and Resources:

The SBMS Industry Engagement Committee hosted zoom seminar at 11am on the 10th August to update staff on the new policies and procedures that have been introduced to govern any industry consulting or research work. The seminar covered aspects relating to previous, current and future industry work as well as strategies for identifying whether your involvement comes under 'consulting' or 'research'.

The recording of the session can be found at 


Industry funding opportunities:

Industry Description of funding opportunity submission info

2021 Research acceleration initiative:

CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organisations. The 2021 Research Acceleration Initiative will focus on research proposals that align with a CSL Therapeutic Area and are amenable to or include a Modality as illustrated below.

Therapeutic areas
  • Immunology
  • Hematology
  • Respiratory
  • Cardiovascular and Metabolic
  • Transplant

Please follow link for more information on focus areas and modalities (pdf).

Successful applications will receive up to $250,000 per year for up to 2 years (max $500,000 funding) to accelerate translation of their research.


online information session:


Monday, 15th February 2021, 4:00pm AEST via Zoom

Dr James Rush, Global New Products Director, Novartis Basel

RSVP to to receive zoom link, by 12th February

Additional information on UniQuest website.


submission deadline:

Friday 5 March 2021


Investigator Initiated Sponsored Research

Takeda and its alliance partners are committed to improving patient care through support of scientific advances in medicine and increasing understanding of important diseases. As part of this commitment, the IISR program supports innovative clinical and basic science studies that address important medical and scientific questions related to our compounds and therapeutic areas of interest.

IISR is defined as unsolicited, independent research where the investigator or the institution (academic, private, or governmental) serves as the Sponsor and Takeda provides support in the form of study drug and/or funding.

IISR proposals are reviewed by Takeda medical and scientific personnel. Decisions are based upon scientific merit as well as alignment with research areas of interest and availability of resources.

Support for an IISR is awarded strictly based on research merit criteria. Support of a study in no way implies any obligation toward or is any way connected to the recommendation or prescribing of Takeda products.

submit an IISR request via their website

For more info see:


Under our mission "to strive towards Better Health and a Brighter Future for people worldwide through leading innovation in medicine", Takeda engages in various open innovation initiatives. In order to accelerate these activities, we launched an open innovation platform called COCKPI-T® in Japan in 2015, where we invite researchers to submit innovative ideas related to therapeutic targets and technologies for drug discovery to gain funding to support their research financially to confirm their concepts. This year we are pleased to announce the start of COCKPI-T® Funding 2020.

Areas of interest:


  • Proposal and validation study of novel therapeutic approaches for rare/intractable diseases associated with neurodegeneration; e.g. ALS, Huntington’s disease and ataxias
  • Molecular mechanism research of disease pathology or reverse translational research with clinical data and samples in frontotemporal dementia, Down syndrome with cognitive decline, or postoperative cognitive dysfunction
  • Proposal of novel therapeutic approaches and validation study for neural disorders which do not fall upon the above (#1 and #2)
  • Novel therapeutic approach to prevent or recover age-related disturbance of neuronal function; e.g. sleep/circadian rhythm, waste clearance, BBB integrity, inflammation, organelle homeostasis, DNA damage, sensory system
  • Definition of novel disease concepts based on biomarker strategy for strict patient stratification, followed by establishment of pathophysiologically-relevant cellular model, and therapeutic approach including gene therapy
  • Novel drug targets, therapeutic concepts and research tool for aberrant glia-neuron network involved in neurodegenerative diseases such as FTLD, PD, ALS, AD.
  • Development of new research tool, drug assay system or drug modality for neurodegenerative disease or rare disease with neurodegenerative pathology

Immunology and Rare Diseases:

  • Regulatory immune cell-focused research applicable to the treatment of neurodegenerative, autoimmune or rare diseases

  • Drug discovery for central nervous system diseases (neurodegenerative diseases, psychiatric disorders) aiming at control of central or peripheral immunity / inflammation

  • Development of CAR-engineered immune cells including T/NK cell products against novel solid and/or hematological malignancies targets

  • Research and development toward realization of innovative technology for next generation cellular cancer immuno-therapy

  • Innovative research to realize immune cell therapies by using cutting-edge technology (e.g. biomaterials, AI)

Platform technologies:

for details see

Submission of non-confidential Proposal Sheet: 

normally June/July - no new dates for 2021

Proposal Sheet (max. three pages) is to be filled out by the applicant based on non-confidential information.

Interview (video-conference): to Mid Nov 


Final selection for COCKPI-T®  Funding winners: December


Pfizer’s Centers for Therapeutic Innovation, or CTI, is a unique joint drug discovery model focused on collaborating with leading academic medical centers to translate and transform concepts into breakthroughs that change patients’ lives.

The CTI 2020 Call for Proposals (CFP) is focused on identifying novel therapeutic opportunities in the areas outlined below and  here (pdf file) with application in Pfizer’s core research focus areas: oncology, inflammation & immunology, internal medicine and rare diseases. The following areas are currently of interest:

  • DNA Damage Response and Replicative Stress
  • Cause or treatment of Repeat Expansion Diseases
  • Cellular Senescence, including senolytic and senomomorphic approaches
  • Tissue-Immune System Crosstalk in disease pathology

Submission entails a non-confidential 2-3 page overview of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

The pre-proposal form and more information can be found here:

no dates yet for 2021